Novo Nordisk
NVO
#31
Rank
ยฃ225.51 B
Marketcap
ยฃ50.70
Share price
-0.93%
Change (1 day)
-54.43%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of March 2025 : ยฃ12.61 Billion

According to Novo Nordisk's latest financial reports the company's total debt is ยฃ12.61 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31ยฃ11.42 B264.04%
2023-12-31ยฃ3.13 B2.29%
2022-12-31ยฃ3.06 B2.13%
2021-12-31ยฃ3.00 B139.3%
2020-12-31ยฃ1.25 B145.01%
2019-12-31ยฃ0.51 B724.61%
2018-12-31ยฃ62.16 M-69.24%
2017-12-31ยฃ0.20 B668.97%
2016-12-31ยฃ26.27 M-75.24%
2015-12-31ยฃ0.10 B40.48%
2014-12-31ยฃ75.53 M213%
2013-12-31ยฃ24.13 M-56.01%
2012-12-31ยฃ54.85 M-42.63%
2011-12-31ยฃ95.6 M-62.82%
2010-12-31ยฃ0.25 B55.61%
2009-12-31ยฃ0.16 B-44.45%
2008-12-31ยฃ0.29 B121.14%
2007-12-31ยฃ0.13 B-1.88%
2006-12-31ยฃ0.13 B-44.53%
2005-12-31ยฃ0.24 B52.72%
2004-12-31ยฃ0.16 B-1.2%
2003-12-31ยฃ0.16 B21.43%
2002-12-31ยฃ0.13 B-25.66%
2001-12-31ยฃ0.18 B-1.56%
2000-12-31ยฃ0.18 B-4.64%
1999-12-31ยฃ0.19 B-25.24%
1998-12-31ยฃ0.25 B-12.2%
1997-12-31ยฃ0.29 B40.78%
1996-12-31ยฃ0.20 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
ยฃ44.92 B 256.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
ยฃ28.22 B 123.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ37.55 B 197.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ16.68 B 32.26%๐Ÿ‡ซ๐Ÿ‡ท France